Medicine price: quote on request. Every case gets a written custom quote before you commit. Your total cost is quoted per case.
We give you a written timeline estimate for your case before you commit.
Ask about Zolgensma

Is Zolgensma available in Saudi Arabia? Status, route and cost

A plain answer for families in Saudi Arabia, checked against FDA, regulator and manufacturer sources on 17 October 2026.

Reviewed by the Reserve Meds clinical operations team on 17 October 2026.

Is Zolgensma available in Saudi Arabia?

Yes. Zolgensma is registered in Saudi Arabia and listed in SFDA's public Drugs List (checked 17 October 2026). It is a one-time gene therapy for spinal muscular atrophy in children under 2, given only at qualified centers. Your specialist refers the patient, and the center confirms eligibility and funding. No import request is normally needed.

  • Registration: Registered in Saudi Arabia: SFDA published a Saudi Public Assessment Report for it in 2022, and it is listed in the SFDA public Drugs List (entry 0510222689), checked 17 October 2026.
  • Access route: Referral to a qualified treatment center in Saudi Arabia (registered, so no import request is normally needed).
  • Who acts: your treating specialist refers the patient; the treatment center accepts the patient and confirms funding.
  • Timeline: We give you a written timeline estimate for your case before you commit.
  • Medicine price: quote on request. Every case gets a written custom quote before you commit.

Status in Saudi Arabia, with dates

  • SFDA published a Saudi Public Assessment Report (summary) for Zolgensma, dated 2022. (source)
  • Zolgensma is listed in the SFDA public Drugs List (entry 0510222689), checked 17 October 2026. (source)

What Zolgensma is

Zolgensma (onasemnogene abeparvovec) is made by Novartis Gene Therapies. The US FDA first approved Zolgensma on 24 May 2019. It is approved for children under 2 years old with spinal muscular atrophy (SMA) caused by mutations in both copies of the SMN1 gene.

How it is given: A single intravenous (IV) infusion given in hospital, with liver tests and monitoring before and after. Timing matters in SMA, so families should speak with the child's neurologist early.

How access works in Saudi Arabia

Because Zolgensma is registered, the usual route is through a qualified treatment center in Saudi Arabia. Your specialist sends a referral with the medical records, the center checks eligibility, and the family confirms funding with the center, an insurer or a government program.

If no local center can treat the patient, for example because of eligibility, center capacity or an age outside the local label, your specialist can refer the patient to a qualified center abroad. A named-patient import is meant for medicines that are not registered, so it is not the usual route here.

Public lists can lag behind decisions, so the treating center or hospital pharmacy confirms the current status before treatment is planned.

Who does what

  • Your treating specialist decides whether Zolgensma is right for the patient and writes the referral or prescription.
  • The hospital or treatment center checks eligibility, plans treatment and is responsible for giving it safely.
  • The Saudi Food and Drug Authority (SFDA) registers medicines and decides on any import request for a medicine that is not registered.
  • Novartis Gene Therapies makes Zolgensma and decides where it can be supplied.
  • Reserve Meds helps your family understand the steps, organizes records and communication, and, where an import is needed, arranges US supply through our licensed wholesale partner. We do not give medical advice.

Documents you will usually need

  • Genetic confirmation of SMA (both copies of SMN1 affected) and the child's age and weight
  • A referral letter from the treating specialist with the diagnosis, past treatments and why this treatment is being considered
  • Recent clinic notes, imaging and laboratory results
  • Identity documents and a funding plan (personal funds, insurer approval or a government treatment decision)
  • Passport and travel documents, if treatment happens abroad

Steps

  1. Referral. Your specialist prepares a referral letter and the medical records.
  2. Center review. A qualified treatment center reviews the records and decides whether the patient is eligible.
  3. Funding. The family confirms funding with the center, an insurer or a government program.
  4. Preparation. The center runs tests and, for cell-based products, collects cells to make the treatment.
  5. Treatment and follow-up. The patient is treated and then followed up by the center and the home specialist.

Timeline and cost

We give you a written timeline estimate for your case before you commit. The treating center, the regulator and the manufacturer set their own timelines.

Medicine price: quote on request. Your total cost depends on the dose, travel or shipping, import steps and coordination. Your coordination fee is quoted in writing for your case before you commit. No hidden charges.

How Reserve Meds helps

Reserve Meds is a digital health company. Medicines are supplied through a US-licensed pharmaceutical wholesale partner. We coordinate access to FDA-approved medicines only. We help your family understand the route, organize records and communication with the hospital or center, and, where an import is approved, arrange US supply and shipping. We do not prescribe, and we do not decide what the regulator or a treatment center approves.

Ask about Zolgensma in Saudi Arabia

Tell us the medicine, your country and a WhatsApp or phone number. We reply within one business day. On WhatsApp we usually reply the same day.

Include the country code, for example +966 or +971.
Message us on WhatsApp

No account needed. We reply within one business day. Your coordination fee is quoted in writing for your case before you commit. No hidden charges.

Frequently asked questions

Is Zolgensma registered in Saudi Arabia?

Yes. Zolgensma is registered in Saudi Arabia and listed in SFDA's public Drugs List (checked 17 October 2026). Public lists can lag behind registration decisions, so the hospital pharmacy confirms the status in SFDA's system before anything is filed.

How do patients in Saudi Arabia get Zolgensma?

It is a one-time gene therapy for spinal muscular atrophy in children under 2, given only at qualified centers. Your specialist refers the patient, and the center confirms eligibility and funding. No import request is normally needed.

How long does it take to get Zolgensma in Saudi Arabia?

We give you a written timeline estimate for your case before you commit. The treating center, the regulator and the manufacturer set their own timelines, and we tell you honestly what depends on them.

How much does Zolgensma cost?

Medicine price: quote on request. Your total cost, including any travel, shipping, import steps and coordination, is quoted in writing for your case before you commit. No hidden charges.

Can Zolgensma be given in Saudi Arabia instead of abroad?

Yes, if a qualified center in Saudi Arabia accepts the patient. Ask your specialist which centers offer it today.

Sources

Checked on 17 October 2026. Regulator rules and lists change. Your hospital pharmacy or treatment center confirms the current position before anything is filed.

  1. FDA: ZOLGENSMA (onasemnogene abeparvovec-xioi) product page, first approved 24 May 2019
  2. SFDA: Saudi Public Assessment Report (summary) for Zolgensma, 2022
  3. SFDA: public Drugs List (all 9,173 entries searched by brand and generic name on 17 Oct 2026)

Related

WhatsApp